Navigation Links
US Regulator Sees No Link Between Tamiflu And Japan Deaths

There is no evidence of a link between Tamiflu and the sudden deaths of 12 children in Japan who took the drug, The US Food and Drug Administration has concluded.

Roche, the Swiss pharmaceutical giant which markets the // drug standing in the front line of defense against a bird flu pandemic, agreed to work on changing the drug's labeling to warn of potential dermatological side-effects, reports AFP.

But the powerful US medicines regulator found unanimously that there was no 'causal link between pediatric deaths and neuropsychiatric adverse events and Tamiflu,' an FDA statement said after a hearing of its paediatric safety panel.

Roche said it 'intends to work with the FDA to change the drug's labeling based on adverse skin events that have occurred in a small number of patients, mostly in Japan.'

'We welcome the outcome of the FDA advisory committee and look forward to working with the FDA and other health authorities to extend our knowledge of the use of Tamiflu and its safety profile,' said William Burns, head of Roche's pharma division. 'The positive role of Tamiflu remains unchanged,' he added.

Reports in Japan have said Tamiflu may have been a factor in several suicides by children aged under 16 who took Tamiflu to treat influenza. The FDA has detailed 75 cases of mental and skin disorders worldwide, including 69 in Japan. The European Union's drugs agency has also asked Roche for a safety review into the drug.

Documents posted on the FDA website attributed increased reports of psychiatric disorders among Japanese children who have taken Tamiflu to a variety of probable causes. Those included increased awareness of flu-associated brain disease, increased access to Tamiflu in Japan, and an accompanying focus by the media and health regulators on potential side-effects.

Countries have placed huge orders for Tamiflu to guard against a feared pandemic of flu that could derive from the H5N1 avian influ enza virus.

The strain has killed more than 60 people in Southeast Asia since 2003 and since last month has been found in Europe, Canada and the Middle East.

Japan has become the single-biggest purchaser of Tamiflu. A health ministry report Monday said that in the worst-case scenario of a mass flu outbreak, up to 640,000 people could die in the densely populated country.

Tamiflu was one of eight drugs being reviewed by the FDA committee 12 months after they were approved for use by children.

Roche insisted to the FDA hearing that Tamiflu is safe, and that more than 30 million people worldwide -- including 11.6 million under-16 in Japan and the United States -- have taken the influenza treatment safely since 2001.

Approximately three to five million people worldwide catch flu each year, resulting in 250,000-500,000 deaths, according to statistics from the WHO.
'"/>




Related medicine news :

1. Tumor Suppressor p53s Contradictory Regulatory System
2. A brush with the U.S. Regulators can cost a fortune
3. Cancer-causing Property Of Teflon Leaves US Regulators Concerned
4. Human Complexity Can Be Attributed To Regulatory Sequence
5. Regulators Object Drug Produced from Genetically Engineered Farm Animals
6. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
7. Medtronic’s Insulin Pump Receives Regulatory Approva
8. Australian Drug Regulators Call for Revamp On The Pharmaceutical Surveillance
9. Drug Regulators Need To Think In Long-Term, Say Charities
10. Regulatory T-cells – Protector or Cause of Diseases
11. European Regulators Investigate Common Painkiller Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology: